AMENDMENTS TO CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) Use of ~~a pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate for the treatment of affections of the peripheral nervous system and/or for stimulating the regeneration of nerves.

2. (original) Use according to claim 1, wherein the affections of the peripheral nervous system concern polyneuropathies, neuritides and/or myopathies.

3. (original) Use according to claim 2, wherein the polyneuropathies, neuritides and myopathies concern degenerative diseases of the spinal column, diabetic polyneuropathies, polyneuropathies after alcohol abusus, other toxic polyneuropathies, facial nerve paresis, face neuralgias, multiple sclerosis, root neuritides, cervical syndrome, shoulder-arm syndrome, ischialgia, lumbago, intercostal neuralgia, trigeminus neuralgia and/or herpes zoster.

4. (currently amended) Use according to ~~any previous~~ claim 1, wherein ~~the pyrimidine nucleotide is uridine-5'-monophosphate, uridine-5'-diphosphate, uridine-5'-triphosphate,~~ uridine-5'-monophosphate or cytidine-5'-monophosphate is cytidine-5'-monophosphate ~~, cytidine-5'-diphosphate, or cytidine-5'-triphosphate~~.

5. (currently amended) Use according to claim ~~4~~ 1, wherein ~~the pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate is uridine-5'-monophosphate.

6. (currently amended) Use according to ~~any previous~~ claim 1, wherein ~~the pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate is administered in a daily dose rate of 1 - 100 mg, preferably of 5 - 50 mg and most preferably of 7 to 40 mg.

7. (currently amended) Use of ~~a pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate for the manufacture of a pharmaceutical composition for the treatment of affections of the peripheral nervous system and/or for the stimulation of the regeneration of nerves.

8. (currently amended) Pharmaceutical composition comprising ~~a pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate as pharmaceutically active ingredient optionally together with physiologically acceptable carriers, adjuvants and/or diluents.

9. (currently amended) Pharmaceutical composition according to claim 8, wherein the single pharmaceutical composition contains ~~the pyrimidine nucleotide~~ uridine-5'-monophosphate or cytidine-5'-monophosphate in a concentration of 1 - 100 mg, preferably 5 - 50 mg and most preferably 7 - 40 mg.

10. (currently amended) Pharmaceutical composition according to claim 8 ~~or 9~~, wherein the pharmaceutical composition is suitable for oral application or injection.

11. (new) Use according to claim 5, wherein the affections of the peripheral nervous system concern polyneuropathies, neuritides and/or myopathies.

12. (new) Use according to claim 11, wherein the polyneuropathies, neuritides and myopathies concern degenerative diseases of the spinal column, diabetic polyneuropathies, polyneuropathies after alcohol abusus, other toxic polyneuropathies, facial nerve paresis, face neuralgias, multiple sclerosis, root neuritides, cervical syndrome, shoulder-arm syndrome, ischialgia, lumbago, intercostal neuralgia, trigeminus neuralgia and/or herpes zoster.

13. (new) Use according to claim 2, wherein uridine-5'-monophosphate or cytidine-5'-monophosphate is administered in a daily dose rate of 1 - 100 mg, preferably of 5 - 50 mg and most preferably of 7 to 40 mg.

14. (new) Use according to claim 3, wherein uridine-5'-monophosphate or cytidine-5'-monophosphate is administered in a daily dose rate of 1 - 100 mg, preferably of 5 - 50 mg and most preferably of 7 to 40 mg.

15. (new) Use according to claim 4, wherein cytidine-5'-monophosphate is administered in a daily dose rate of 1 - 100 mg, preferably of 5 - 50 mg and most preferably of 7 to 40 mg.

16. (new) Use according to claim 5, wherein uridine-5'-monophosphate is administered in a daily dose rate of 1 - 100 mg, preferably of 5 - 50 mg and most preferably of 7 to 40 mg.

17. (new) Pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is suitable for oral application or injection.